Prostate cancer, from Aifa ok to reimbursability of first radioligand
MILAN (ITALPRESS) – With the approval of Lutetium (177Lu) vipivotide tetraxetan for reimbursability by the CDA of the Agenzia Italiana del Farmaco, radioligand-based precision therapy will soon become accessible for Italian patients with progressive metastatic castration-resistant prostate cancer (mCRPC), prostate-specific […]
Prostate cancer, from Aifa ok to reimbursability of first radioligand Read More »